As of the end of the third quarter of this year, Lancy Co., Ltd. (002612.SZ) has a total of 41 medical beauty institutions, including: 11 comprehensive hospitals; 30 outpatient clinics and clinics. Since the beginning of this year, by acquiring the targets held by the fund for extracorporeal medical beauty industry, 3 comprehensive medical beauty hospitals have been added. In addition, the company's Jinfu Medical Beauty has laid out a business development strategy around community-oriented and lifestyle-oriented, already establishing 5 lifestyle beauty institutions under the sub-brand "Crystal Skin Master". In the first three quarters of this year, the medical beauty business sector achieved revenue of approximately 2.071 billion yuan, with non-surgical business (light medical beauty business) accounting for about 85% of the revenue. Currently, the company has layouts in Beijing, Chengdu, Xi'an, Kunming, Chongqing, Shenzhen, Wuhan, Zhengzhou, Changsha and other regions, radiating to South China, Central China, and other southwestern regions, moving towards the strategic layout of national medical beauty.

- Headlines
- As of the end of the third quarter of this year, lancy co.,ltd. has already established 41 medical beauty institutions.
朗姿股份(002612.SZ):截至今年三季度末,公司已拥有41家医疗美容机构
As of the end of the third quarter of this year, lancy co.,ltd. has already established 41 medical beauty institutions.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got It
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got It
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Price
Log In for the Full List
Latest
10:33
The Chinext Price Index has increased by 2%, the Shanghai Composite Index is currently up 1.21%, and the Shenzhen Component Index is currently up 1.5%.
Chinext Price Index+1.83%
10:33
Multiple Gold ETFs increased by over 3%.
HUANGJINETF+1.63%
10:32
The State-owned Assets Supervision and Administration Commission's work plan for formulating regulations in 2025 will revise the "Management Measures for the Development Planning of Central Enterprises" and others.
Investment Course

Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.